Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia
Neurocrine presented real-world evidence at the Endocrine Nurses Society Symposium 2026 mapping how classic congenital adrenal hyperplasia burdens patients across their lifetimes. The CAHtalog registry analysis combined decades of medical records from 10 adults covering more than 300 patient-years, alongside new 2-year CAHtalyst data showing crinecerfont enables sustained glucocorticoid dose reductions with improved clinical and cardiometabolic outcomes.
Key figures
- Drug Name
- CRENESSITY (crinecerfont)
- Phase Of Trial
- Phase 3
- Patient years
- more than 300
- Cahtalog patients
- 10
- Cah relevant events
- more than 2,800
- Cahtalyst adult patients
- 182
- Cahtalyst total patients
- 285
- Cahtalyst pediatric patients
- 103
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.